Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC.

Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA.

Life Sci Alliance. 2019 May 27;2(3). pii: e201900328. doi: 10.26508/lsa.201900328. Print 2019 Jun.

2.

Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFβ1.

Sippel TR, Johnson AM, Li HY, Hanson D, Nguyen TT, Bullock BL, Poczobutt JM, Kwak JW, Kleczko EK, Weiser-Evans MC, Nemenoff RA.

Mol Cancer Res. 2019 Aug;17(8):1748-1758. doi: 10.1158/1541-7786.MCR-19-0236. Epub 2019 May 14.

PMID:
31088909
3.

Defining the Cell Types That Drive Idiopathic Pulmonary Fibrosis Using Single-Cell RNA Sequencing.

Poczobutt JM, Eickelberg O.

Am J Respir Crit Care Med. 2019 Jun 15;199(12):1454-1456. doi: 10.1164/rccm.201901-0197ED. No abstract available.

4.

Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II.

Li HY, McSharry M, Walker D, Johnson A, Kwak J, Bullock B, Neuwelt A, Poczobutt JM, Sippel TR, Keith RL, Weiser-Evans MCM, Clambey E, Nemenoff RA.

Oncoimmunology. 2018 Feb 13;7(5):e1423182. doi: 10.1080/2162402X.2017.1423182. eCollection 2018.

5.

Bone marrow-derived cPLA2α contributes to renal fibrosis progression.

Montford JR, Lehman AMB, Bauer CD, Klawitter J, Klawitter J, Poczobutt JM, Scobey M, Weiser-Evans M, Nemenoff RA, Furgeson SB.

J Lipid Res. 2018 Feb;59(2):380-390. doi: 10.1194/jlr.M082362. Epub 2017 Dec 11.

6.

Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.

Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, Weiser-Evans MC, Lambris JD, Clambey ET, Thurman JM, Nemenoff RA.

Cancer Res. 2018 Jan 1;78(1):143-156. doi: 10.1158/0008-5472.CAN-17-0240. Epub 2017 Nov 8.

7.

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.

Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA.

Cancer Immunol Res. 2017 Sep;5(9):767-777. doi: 10.1158/2326-6066.CIR-16-0365. Epub 2017 Aug 17.

8.

Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer.

Poczobutt JM, De S, Yadav VK, Nguyen TT, Li H, Sippel TR, Weiser-Evans MC, Nemenoff RA.

J Immunol. 2016 Mar 15;196(6):2847-59. doi: 10.4049/jimmunol.1502364. Epub 2016 Feb 12.

9.

Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment.

Poczobutt JM, Nguyen TT, Hanson D, Li H, Sippel TR, Weiser-Evans MC, Gijon M, Murphy RC, Nemenoff RA.

J Immunol. 2016 Jan 15;196(2):891-901. doi: 10.4049/jimmunol.1501648. Epub 2015 Dec 11.

10.

Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment.

Poczobutt JM, Gijon M, Amin J, Hanson D, Li H, Walker D, Weiser-Evans M, Lu X, Murphy RC, Nemenoff RA.

PLoS One. 2013 Nov 11;8(11):e79633. doi: 10.1371/journal.pone.0079633. eCollection 2013.

11.

Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism.

Prescott JD, Poczobutt JM, Tentler JJ, Walker DM, Gutierrez-Hartmann A.

Mol Cancer. 2011 Aug 28;10:103. doi: 10.1186/1476-4598-10-103.

12.

Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells.

Poczobutt JM, Tentler J, Lu X, Schedin PJ, Gutierrez-Hartmann A.

BMC Cancer. 2010 Jul 16;10:373. doi: 10.1186/1471-2407-10-373.

13.

Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.

Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR.

Thyroid. 2009 Aug;19(8):825-35. doi: 10.1089/thy.2008.0362.

Supplemental Content

Loading ...
Support Center